Clinical trial
Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP
NCT00204308 · University of North Carolina, Chapel Hill, Other · Completed
Key facts
| NCT number | NCT00204308 |
|---|---|
| Title | Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP |
| Official title | Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission |
| Acronym | TD-2 |
| Lead sponsor | University of North Carolina, Chapel Hill, Other |
| Collaborators | Elizabeth Glaser Pediatric AIDS Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV, Pregnancy |
| Intervention type | Drug |
| Interventions | Combination tenofovir-emtricitabine |
| Enrollment | 400 |
| Start date | Mar 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 20, 2005 |
| Last update posted | May 31, 2012 |
| Countries | Zambia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: